January 1, 2022 - December 31, 2022
January 1, 2021 - December 31, 2021
-
Consolidated Financial Summary Fiscal 2021 Second Quarter
（720KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2021 Second Quarter
（889KB）
-
Results Presentation Fiscal 2021 Second Quarter
（566KB）
-
Revenues from other products
（25KB）
-
Transcript of Results Briefing Fiscal 2021 Second Quarter (text)
（1,500KB）
January 1, 2020 - December 31, 2020
-
Consolidated Financial Summary Fiscal 2020
（601KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2020
（345KB）
-
Results Presentation Fiscal 2020
（448KB）
-
Summary of late-stage clinical trials
（566KB）
-
Revenues from other products
（25KB）
-
Transcript of FY 2020 Results/2021-2025 Medium Term Business Plan Briefing (text)
（2,712KB）
-
Consolidated Financial Summary Fiscal 2020 Interim
（2,121KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2020 Interim
（573KB）
-
Results Presentation Fiscal 2020 Interim
（735KB）
-
Summary of clinical trials
（627KB）
-
Revenues from other products
（22KB）
-
Transcript of Results Presentation Fiscal 2020 Interim (text)
（1,274KB）
January 1, 2019 - December 31, 2019
-
Consolidated Financial Summary Fiscal 2019
（452KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019
（765KB）
-
Results Presentation Fiscal 2019
（1,045KB）
-
Summary of late-stage clinical trials
（187KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 (text)
（1,499KB）
-
Consolidated Financial Summary Fiscal 2019 Interim
（251KB）
-
Appendix to the Consolidated Financial Summary Fiscal 2019 Interim
（490KB）
-
Results Presentation Fiscal 2019 Interim
（740KB）
-
Summary of late-stage clinical trials
（227KB）
-
Revenues from other products
（23KB）
-
Transcript of Results Presentation Fiscal 2019 Interim (text)
（1,035KB）
Kyowa Kirin R&D Meeting
December 5, 2022
-
R&D Meeting Presentation
（1,896KB）
-
Transcript (Text)
（3,368KB）
This document is used only for the purpose of providing the information to investors. Though it may contain the information concerning pharmaceutical products (including products under development), it is not for the purpose of promotion, advertising, or medical advice.
Kyowa Kirin ESG Meeting
October 12, 2022
-
ESG Meeting Presentation
（11,701KB）
-
Transcript (text)
（12,267KB）
40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
-
Presentation material
（4,623KB）
-
Transcript (text)
（2,600KB）
- Presentation (webcast)
The webcast will be available until January 13, 2023.
Update on KHK4083
October 4, 2021 (Material added on November 5, 2021)
-
Pathogenesis and Latest Therapy of Atopic Dermatitis
（673KB）
-
EADV Follow-up
（456KB）
-
ISDS Presentation (Nov. 5 added)
（482KB）
-
Transcript (text)
（3,492KB）
Kyowa Kirin ESG Briefing
September 8, 2021
-
ESG Briefing Presentation
（6,515KB）
-
Transcript (text)
（6,250KB）
Joint Development and Commercial Agreement of KHK4083 with Amgen
June 1, 2021
-
Presentation
（333KB）
-
Transcript (text)
（951KB）
- News Release
R&D Day
December 10, 2020
-
R&D Day Presentation
（1,406KB）
-
Transcript (text)
（2,871KB）
Updates on Nourianz marketing strategy in the U.S. and KW-6356 development
November 19, 2019
-
Agenda
（101KB）
-
2019 US NOURIANZ Commercial Update
（2,170KB）
-
A Phase 2a Study of KW-6356 in the Subjects with Parkinson's Disease
（1,398KB）
-
Transcript (text)
（2,086KB）
Update on KHK4083: A phase 1 study in subjects with atopic dermatitis
December 3, 2018
-
Agenda
（78KB）
-
A phase 1 study of KHK4083 in subjects with atopic dermatitis
（1,043KB）
Update on burosumab (KRN23): Clinical and regulatory updates, and pre-launch activities in the US and EU
October 27, 2017
-
February 07, 2023
Appendix to the Consolidated Financial Summary Fiscal 2022
（1,444KB）
-
February 07, 2023
Consolidated Financial Summary Fiscal 2022
（819KB）
-
December 06, 2022
Notice Concerning Record of Inpairment Loss and Revisions to Financial Earnings Forecast
（207KB）
-
December 06, 2022
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
（230KB）
-
November 04, 2022
Appendix to the Consolidated Financial Summary Fiscal 2022 Third Quarter
（1,494KB）
